Enzyme Therapy Brings Relief in Fabry’s Disease
Wednesday, December 9th, 2009
Patients with Fabry’s disease improved their cardiac hypertrophy, reduced their pain, and improved their quality of life after five years of agalsidase alfa enzyme replacement therapy, according to a study published online Dec. 2 in The Lancet.